Finding better ways to treat cancer
Bolt Biotherapeutics (boltbio.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 58th percentile of 19234 Healthcare brands.
Bolt Biotherapeutics is a biotechnology company focused on developing immune-activating cancer therapies. Its approach leverages the innate immune system's pattern recognition receptors to help the body naturally identify and eliminate tumor cells. The company's flagship platform, Boltbody ISAC (Immune-Stimulating Antibody Conjugate), combines targeted antibodies with immune-activating agents. Bolt's mission is to harness the immune system to improve patient outcomes and eradicate cancer, working with oncologists, biopharmaceutical partners, and the broader medical research community.
| Brand Name | Bolt Biotherapeutics |
|---|---|
| Domain | boltbio.com |
| Industry | Healthcare |
| Main Competitors | Mersana Therapeutics (78/100), Seagen (84/100), ImmunoGen (66/100), Silverback Therapeutics, Shattuck Labs (77/100), Innate Pharma (69/100), Compugen (82/100) |
Moz Domain Authority 36/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,987,921 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Bolt is leveraging the immune system for a better way to treat cancer. Our approach works with a person" (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Bolt Biotherapeutics?", Claude could identify the brand as of October 2026. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing Boltbody immune-stimulating antibody conjugates (ISACs), which combine tumor-targeting antibodies with immune-activating agonists to fight cancer. Its lead candidate, BDC-1001, targets HER2-expressing t Best known for Developing Boltbody immune-stimulating antibody conjugates (ISACs) for cancer immunotherapy.
When asked "Best brands similar to Bolt Biotherapeutics?", Claude would recommend Bolt Biotherapeutics as of October 2026. It's a notable name in the emerging ISAC and antibody-drug conjugate space for oncology, so I'd mention it if someone asked about innovative cancer immunotherapy biotechs.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Bolt Biotherapeutics's main competitors in Healthcare: Mersana Therapeutics (78/100), Seagen (84/100), ImmunoGen (66/100), Shattuck Labs (77/100), Innate Pharma (69/100).
Sources: Brand Analyzer scan
Bolt Biotherapeutics has low AI-search visibility, scoring 23/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 39, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics offers immune-activating cancer therapeutics developed through its Boltbody ISAC (Immune-Stimulating Antibody Conjugate) platform, which is designed to help the immune system recognize and eliminate tumor cells.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics is a biotechnology company that develops immune-activating therapies for cancer treatment, leveraging the body's innate immune system to target and eliminate tumor cells.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics designs and develops cancer therapies that activate the innate immune system's pattern recognition receptors, helping the body naturally recognize and destroy tumor cells. Its work centers on the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines antibody targeting with immune activation to treat cancer.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics is known for its Boltbody ISAC (Immune-Stimulating Antibody Conjugate) platform, an approach that combines antibody-based tumor targeting with activation of the innate immune system to fight cancer.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics' work is intended for cancer patients as ultimate beneficiaries, while its direct partners and users include oncologists, biopharmaceutical companies, and the medical research community engaged in developing and evaluating novel immune-based cancer therapies.
Sources: Bolt Biotherapeutics official site
Bolt Biotherapeutics scores 23/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Bolt Biotherapeutics has a weak AI-visibility profile at 23/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #2,987,921 (Tranco), open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 36/100. In a live check, Claude could already identify Bolt Biotherapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Bolt Biotherapeutics: International BodyTalk Association (77/100), Berkeley Media Studies Group (77/100), Bonitas (77/100), ANNEMARIE BÖRLIND (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.